Title:
AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS
Document Type and Number:
WIPO Patent Application WO/2016/114322
Kind Code:
A1
Abstract:
The present invention provides an agent for the prevention and/or treatment of amyotrophic lateral sclerosis (ALS), the agent containing: one or more kinase inhibitors selected from the group consisting of epidermal growth factor receptor (EGFR) inhibitors, fibroblast growth factor receptor (FGFR) inhibitors, aurora kinase inhibitors, protein kinase A (PKA) inhibitors, protein kinase C (PKC) inhibitors, MEK inhibitors, Met inhibitors, JNK inhibitors, Syk inhibitors, and JAK inhibitors; prostaglandin analogs; estrogen receptor antagonists; or one or more compounds selected from the group consisting of tivozanib and analogs thereof, SB 216763, Cdk2 inhibitor II, BUDESONIDE, RIBOFLAVIN, alpha-TOCHOPHEROL, AMODIAQUINE, SU9516, sunitinib and analogs thereof, GSK-3 inhibitor XIII, bisindolylmaleimide I, HYDROQUINONE, FLUNISOLIDE, MGCD-265, indirubin-3'-monoxime, HYDRASTINE (1R,9S), PIPERINE, BUTAMBEN, axitinib and analogs thereof, APOMORPHINE, FENBUFEN, bosutinib (SKI-606) and analogs thereof, Wee1 inhibitor, Cdk2 inhibitor IV, NU6140, 3-hydroxybutyric acid, AT9283, imatinib, nilotinib, rebastinib, and bafetinib. In particular, the use of compounds already marketed as pharmaceuticals makes it possible to develop a pharmaceutical for ALS prevention and/or treatment rapidly and at low cost.
Inventors:
INOUE HARUHISA (JP)
IMAMURA KEIKO (JP)
IMAMURA KEIKO (JP)
Application Number:
PCT/JP2016/050883
Publication Date:
July 21, 2016
Filing Date:
January 13, 2016
Export Citation:
Assignee:
UNIV KYOTO (JP)
International Classes:
A61K45/00; A61K31/277; A61K31/416; A61K31/4365; A61K31/4433; A61K31/496; A61K31/505; A61K31/506; A61K31/5377; A61P21/00
Domestic Patent References:
| WO2010098888A1 | 2010-09-02 | |||
| WO2004091663A1 | 2004-10-28 | |||
| WO2012048330A2 | 2012-04-12 | |||
| WO2010065162A1 | 2010-06-10 | |||
| WO2008031835A2 | 2008-03-20 | |||
| WO2006042362A1 | 2006-04-27 |
Foreign References:
| JP2014502974A | 2014-02-06 | |||
| JP2013518810A | 2013-05-23 |
Other References:
LE PICHON ET AL.: "EGFR inhibitor erlotinib delays disease progression but does not extend survival in the SOD1 mouse model of ALS", PLOS ONE, vol. 8, no. 4, 2013, pages e62342, XP002764060
HASHIOKA S. ET AL.: "Interferon-y-dependent cytotoxic activation of human astrocytes and astrocytoma cells", NEUROBIOLOGY OF AGING, vol. 30, no. 12, 2009, pages 1924 - 1935, XP026692386
KYUNG-MIN NOH ET AL.: "A Novel Neuroprotective Mechanism of Riluzole:Direct Inhibition of Protein Kinase C", NEUROBIOLOGY OF DISEASE, vol. 7, 2000, pages 375 - 383, XP055465346
VELDINK, JAN H. ET AL.: "Intake of polyunsaturated fatty acids and vitamin E reduces the risk of developing amyotrophic lateral sclerosis", JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY, vol. 78, no. 4, 2007, pages 367 - 371, XP055465347
MEAD, RICHARD J. ET AL.: "S[+], Apomorphine is a CNS penetrating activator of the Nrf2-ARE pathway with activity in mouse and patient fibroblast models of amyotrophic lateral sclerosis", FREE RADICAL BIOLOGY & MEDICINE, vol. 61, 2013, pages 438 - 452, XP055465348
LIANG, JIANFENG ET AL.: "delta-Opioid receptors up- regulate excitatory amino acid transporters in mouse astrocytes", BRITISH JOURNAL OF PHARMACOLOGY, vol. 171, no. 23, 2014, pages 5417 - 5430, XP055465349
TSUCHIOKA, M. ET AL.: "Riluzole-induced glial cell line-derived neurotrophic factor production is regulated through fibroblast growth factor receptor signaling in rat C6 glioma cells", BRAIN RESEARCH, vol. 1384, 2011, pages 1 - 8, XP028156756
MADEIRA, JOCELYN M. ET AL.: "Cobalt(II) beta- ketoaminato complexes as novel inhibitors of neuroinflammation", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 1, no. 3, 2012, pages 81 - 88
See also references of EP 3246046A4
HASHIOKA S. ET AL.: "Interferon-y-dependent cytotoxic activation of human astrocytes and astrocytoma cells", NEUROBIOLOGY OF AGING, vol. 30, no. 12, 2009, pages 1924 - 1935, XP026692386
KYUNG-MIN NOH ET AL.: "A Novel Neuroprotective Mechanism of Riluzole:Direct Inhibition of Protein Kinase C", NEUROBIOLOGY OF DISEASE, vol. 7, 2000, pages 375 - 383, XP055465346
VELDINK, JAN H. ET AL.: "Intake of polyunsaturated fatty acids and vitamin E reduces the risk of developing amyotrophic lateral sclerosis", JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY, vol. 78, no. 4, 2007, pages 367 - 371, XP055465347
MEAD, RICHARD J. ET AL.: "S[+], Apomorphine is a CNS penetrating activator of the Nrf2-ARE pathway with activity in mouse and patient fibroblast models of amyotrophic lateral sclerosis", FREE RADICAL BIOLOGY & MEDICINE, vol. 61, 2013, pages 438 - 452, XP055465348
LIANG, JIANFENG ET AL.: "delta-Opioid receptors up- regulate excitatory amino acid transporters in mouse astrocytes", BRITISH JOURNAL OF PHARMACOLOGY, vol. 171, no. 23, 2014, pages 5417 - 5430, XP055465349
TSUCHIOKA, M. ET AL.: "Riluzole-induced glial cell line-derived neurotrophic factor production is regulated through fibroblast growth factor receptor signaling in rat C6 glioma cells", BRAIN RESEARCH, vol. 1384, 2011, pages 1 - 8, XP028156756
MADEIRA, JOCELYN M. ET AL.: "Cobalt(II) beta- ketoaminato complexes as novel inhibitors of neuroinflammation", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 1, no. 3, 2012, pages 81 - 88
See also references of EP 3246046A4
Attorney, Agent or Firm:
TAKASHIMA, HAJIME (JP)
Takashima 1 (JP)
Takashima 1 (JP)
Download PDF: